Form 4: Cue Biopharma Director Receives RSU Grant

Pamela Garzone, a Director at Cue Biopharma, Inc., has been granted 21,800 Restricted Stock Units (RSUs) vesting over three years.

Summary

• Pamela Garzone, a Director of Cue Biopharma, Inc., received a grant of 21,800 Restricted Stock Units (RSUs) on July 9, 2026.
• The RSUs are subject to a vesting schedule, with one-third vesting on July 9, 2027, another third on July 9, 2028, and the final third on July 9, 2029.
• Vesting is contingent upon Ms. Garzone's continued service with the company through each respective vesting date.
• Following this transaction, Ms. Garzone beneficially owns 21,800 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard compensation event for a director rather than a significant financial or strategic development for the company.

Positives

• Grant of RSUs to a Director indicates a commitment to retaining key leadership and aligning their interests with shareholders.
• The staggered vesting schedule over three years incentivizes long-term commitment and performance.
• The grant is structured to reward continued service, promoting stability within the board.

Negatives

• The filing does not provide details on the valuation of the RSU grant at the time of issuance.
• No specific performance metrics are tied to the vesting of these RSUs, beyond continued employment.

Risks

• The value of the RSUs is subject to the future performance of Cue Biopharma's stock price.
• If Ms. Garzone's service with the company terminates before a vesting date, the unvested portion of the RSUs will be forfeited.

Future Outlook

The future outlook for the RSU grant is tied to the continued service of Pamela Garzone and the performance of Cue Biopharma's stock, with vesting occurring in tranches over the next three years.

Management Comments

• The grant of RSUs is subject to the reporting person's continued service with the issuer through each such vest date.

Industry Context

StockSavvy.ai notes that grants of Restricted Stock Units (RSUs) to directors are a common practice in the biotechnology and pharmaceutical sectors to attract, retain, and incentivize executive and board talent, aligning their financial interests with long-term company value creation.

Stakeholder Impact

• Shareholders: The RSU grant represents a form of compensation that dilutes existing share ownership, but it also serves to retain experienced leadership, which can be beneficial for long-term shareholder value.
• Employees: While not directly impacting most employees, such grants are part of the overall compensation philosophy that can influence company culture and talent retention.
• Management: The grant directly impacts the compensation and incentives of the director receiving the RSUs.

Next Steps

• Continued service by Pamela Garzone through July 9, 2027, for the first tranche of RSUs to vest.
• Continued service by Pamela Garzone through July 9, 2028, for the second tranche of RSUs to vest.
• Continued service by Pamela Garzone through July 9, 2029, for the final tranche of RSUs to vest.

Key Dates

Keywords

Cue Biopharma, CUE, Form 4, Insider Transaction, Restricted Stock Units, RSU Grant, Director Compensation, Beneficial Ownership, Securities Exchange Act